Founded in 2019, Novamind is building a global network of infrastructure to serve the regulated psychedelics industry. With their wholly-owned subsidiaries, Cedar Psychiatry and Cedar Clinical Research, Novamind plans to provide access to safe and legal psychedelic experiences and advance research for psychedelic medicine.
In August 2020, Novamind appointed Reid Robison Chief Medical Officer (CMO). Dr. Robison is a thought leader in psychedelic medicine, widely recognized for his contributions as a clinician and researcher towards the use of psychedelic-assisted psychotherapy in psychiatry.
Novamind Stock IPO
Novamind began trading on the Canadian Securities Exchange (CSE) on January 5th, 2021 under the ticker symbol NM.
Acquisition by Numinus
On June 10, 2022, Numinus (NUMI) acquired Novamind.